A multi-center phase II study to investigate the safety and activity of SDX-105 (bendamustine) in patients with indolent non-Hodgkin's lymphoma (NHL) who are refractory to rituximab
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2014
At a glance
- Drugs Bendamustine (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cephalon
- 09 Nov 2007 Status change from in progress to completed.
- 25 Sep 2005 New trial record.